pharma · Friedreich Ataxia · LRMR
Larimar Therapeutics
Larimar Therapeutics patent portfolio — 5 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.
Company details
- Status
- Public
- HQ
- Bala Cynwyd, USA
- Founded
- 2016
- Employees
- 82
- Programs
- 3
- Drugs
- 2
- Patents
- 5
Larimar Therapeutics patents
5 pharmaceutical patents indexed for Larimar Therapeutics. 0 expire within 24 months.
Larimar Therapeutics has 5 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.
Patent portfolio
-
US 12390509
Pharmaceutical composition comprising frataxin fusion protein and methods of use thereof
granted -
US 12351611
Molecules for organelle-specific protein delivery
granted -
US 12091437
Molecules for organelle-specific protein delivery
granted -
US 11976100
Methods for treating myelin associated diseases and mitochondria associated diseases
granted -
US 11891420
Molecules for organelle-specific protein delivery
granted
Frequently asked questions
How many patents does Larimar Therapeutics have?
5 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Larimar Therapeutics patents expire?
0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.